$50MSeries C, 25 March 2026
Rebranded from Vaxess; funds GLP-1 patch trials, manufacturing and a new Boston HQ.
- Amount
- $50M
- Stage
- Series C
- Announced
- 25 March 2026
- Lead
- RA Capital Management
- Other investors
- Engine Ventures, GHIC, SiteGround
- Use of funds
- Rebranded from Vaxess; funds GLP-1 patch trials, manufacturing and a new Boston HQ.
- Checked
- Amount and date matched across 2 press sources
- Sources
- Terrestrial Bio (formerly Vaxess) raises $50M Series C massdevice.com
Terrestrial Bio (formerly Vaxess) raises $50M Series C pulse2.com